Complementary Role of Fibroblast Growth Factor 21 and Cytokeratin 18 in Monitoring the Different Stages of Nonalcoholic Fatty Liver Disease

Abstract Fibroblast growth factor 21 (FGF21) and cytokeratin 18 (CK18) were previously reported to be elevated in nonalcoholic fatty liver disease (NAFLD). We aim to analyze the differential roles of FGF21, cell apoptosis marker CK18 fragment M30 and total cell death marker CK18 M65ED in monitoring...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Guangyu Wu, Huating Li, Qichen Fang, Jing Zhang, Mingliang Zhang, Lei Zhang, Liang Wu, Xuhong Hou, Junxi Lu, Yuqian Bao, Weiping Jia
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2017
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/e5647c645aa74d1cabe7600c6454e690
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e5647c645aa74d1cabe7600c6454e690
record_format	dspace
spelling	oai:doaj.org-article:e5647c645aa74d1cabe7600c6454e6902021-12-02T11:41:01ZComplementary Role of Fibroblast Growth Factor 21 and Cytokeratin 18 in Monitoring the Different Stages of Nonalcoholic Fatty Liver Disease10.1038/s41598-017-05257-52045-2322https://doaj.org/article/e5647c645aa74d1cabe7600c6454e6902017-07-01T00:00:00Zhttps://doi.org/10.1038/s41598-017-05257-5https://doaj.org/toc/2045-2322Abstract Fibroblast growth factor 21 (FGF21) and cytokeratin 18 (CK18) were previously reported to be elevated in nonalcoholic fatty liver disease (NAFLD). We aim to analyze the differential roles of FGF21, cell apoptosis marker CK18 fragment M30 and total cell death marker CK18 M65ED in monitoring the different stages of NAFLD spectrum in a population-based prospective cohort comprising 808 Chinese subjects. Predictive performances for monitoring the different stages of NAFLD were assessed by logistic regression and receiver-operating characteristic (ROC) curves. We found baseline FGF21 but not CK18 level was an independent predictor for the development of simple steatosis. NAFLD patients who had remission during follow-up had significantly lower baseline M30 levels than those who sustained NAFLD (84.74U/L [53.26–135.79] vs. 118.47U/L [87.16–188.89], P = 0.012). M65ED was independently predictive of progressing to suspected non-alcoholic steatohepatitis (NASH) in NAFLD patients. These results suggest that FGF21 can be used for early identification of hepatic steatosis. On the other hand, CK18 including M30 and M65ED, are predictive of the prognosis of NAFLD patients. FGF21 and CK18 might play differential roles and have complementary value in non-invasive identification and monitoring the outcome of NAFLD patients.Guangyu WuHuating LiQichen FangJing ZhangMingliang ZhangLei ZhangLiang WuXuhong HouJunxi LuYuqian BaoWeiping JiaNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 7, Iss 1, Pp 1-10 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Guangyu Wu Huating Li Qichen Fang Jing Zhang Mingliang Zhang Lei Zhang Liang Wu Xuhong Hou Junxi Lu Yuqian Bao Weiping Jia Complementary Role of Fibroblast Growth Factor 21 and Cytokeratin 18 in Monitoring the Different Stages of Nonalcoholic Fatty Liver Disease
description	Abstract Fibroblast growth factor 21 (FGF21) and cytokeratin 18 (CK18) were previously reported to be elevated in nonalcoholic fatty liver disease (NAFLD). We aim to analyze the differential roles of FGF21, cell apoptosis marker CK18 fragment M30 and total cell death marker CK18 M65ED in monitoring the different stages of NAFLD spectrum in a population-based prospective cohort comprising 808 Chinese subjects. Predictive performances for monitoring the different stages of NAFLD were assessed by logistic regression and receiver-operating characteristic (ROC) curves. We found baseline FGF21 but not CK18 level was an independent predictor for the development of simple steatosis. NAFLD patients who had remission during follow-up had significantly lower baseline M30 levels than those who sustained NAFLD (84.74U/L [53.26–135.79] vs. 118.47U/L [87.16–188.89], P = 0.012). M65ED was independently predictive of progressing to suspected non-alcoholic steatohepatitis (NASH) in NAFLD patients. These results suggest that FGF21 can be used for early identification of hepatic steatosis. On the other hand, CK18 including M30 and M65ED, are predictive of the prognosis of NAFLD patients. FGF21 and CK18 might play differential roles and have complementary value in non-invasive identification and monitoring the outcome of NAFLD patients.
format	article
author	Guangyu Wu Huating Li Qichen Fang Jing Zhang Mingliang Zhang Lei Zhang Liang Wu Xuhong Hou Junxi Lu Yuqian Bao Weiping Jia
author_facet	Guangyu Wu Huating Li Qichen Fang Jing Zhang Mingliang Zhang Lei Zhang Liang Wu Xuhong Hou Junxi Lu Yuqian Bao Weiping Jia
author_sort	Guangyu Wu
title	Complementary Role of Fibroblast Growth Factor 21 and Cytokeratin 18 in Monitoring the Different Stages of Nonalcoholic Fatty Liver Disease
title_short	Complementary Role of Fibroblast Growth Factor 21 and Cytokeratin 18 in Monitoring the Different Stages of Nonalcoholic Fatty Liver Disease
title_full	Complementary Role of Fibroblast Growth Factor 21 and Cytokeratin 18 in Monitoring the Different Stages of Nonalcoholic Fatty Liver Disease
title_fullStr	Complementary Role of Fibroblast Growth Factor 21 and Cytokeratin 18 in Monitoring the Different Stages of Nonalcoholic Fatty Liver Disease
title_full_unstemmed	Complementary Role of Fibroblast Growth Factor 21 and Cytokeratin 18 in Monitoring the Different Stages of Nonalcoholic Fatty Liver Disease
title_sort	complementary role of fibroblast growth factor 21 and cytokeratin 18 in monitoring the different stages of nonalcoholic fatty liver disease
publisher	Nature Portfolio
publishDate	2017
url	https://doaj.org/article/e5647c645aa74d1cabe7600c6454e690
work_keys_str_mv	AT guangyuwu complementaryroleoffibroblastgrowthfactor21andcytokeratin18inmonitoringthedifferentstagesofnonalcoholicfattyliverdisease AT huatingli complementaryroleoffibroblastgrowthfactor21andcytokeratin18inmonitoringthedifferentstagesofnonalcoholicfattyliverdisease AT qichenfang complementaryroleoffibroblastgrowthfactor21andcytokeratin18inmonitoringthedifferentstagesofnonalcoholicfattyliverdisease AT jingzhang complementaryroleoffibroblastgrowthfactor21andcytokeratin18inmonitoringthedifferentstagesofnonalcoholicfattyliverdisease AT mingliangzhang complementaryroleoffibroblastgrowthfactor21andcytokeratin18inmonitoringthedifferentstagesofnonalcoholicfattyliverdisease AT leizhang complementaryroleoffibroblastgrowthfactor21andcytokeratin18inmonitoringthedifferentstagesofnonalcoholicfattyliverdisease AT liangwu complementaryroleoffibroblastgrowthfactor21andcytokeratin18inmonitoringthedifferentstagesofnonalcoholicfattyliverdisease AT xuhonghou complementaryroleoffibroblastgrowthfactor21andcytokeratin18inmonitoringthedifferentstagesofnonalcoholicfattyliverdisease AT junxilu complementaryroleoffibroblastgrowthfactor21andcytokeratin18inmonitoringthedifferentstagesofnonalcoholicfattyliverdisease AT yuqianbao complementaryroleoffibroblastgrowthfactor21andcytokeratin18inmonitoringthedifferentstagesofnonalcoholicfattyliverdisease AT weipingjia complementaryroleoffibroblastgrowthfactor21andcytokeratin18inmonitoringthedifferentstagesofnonalcoholicfattyliverdisease
_version_	1718395492334829568

Complementary Role of Fibroblast Growth Factor 21 and Cytokeratin 18 in Monitoring the Different Stages of Nonalcoholic Fatty Liver Disease

Ejemplares similares